EraGen Wins NIAID Grant For Bioweapon Diagnostics

EraGen Biosciences has won a biodefense grant worth nearly $1 million from the National Institute of Allergy and Infectious Diseases to develop diagnostics for bioweapons detection.

Under the two-and-a-half-year grant, EraGen will modify its GeneCode sample-quantitation and genotyping technology to detect several Category A bioweapon agents — those that the US Centers for Disease Control and Prevention has determined would cause the greatest harm if intentionally released.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.